Drugs / LX1033
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01411800 | Aug → Oct 2011 | irritable bowel syndrome | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01494233 | Feb 2012 → Sep 2013 | irritable bowel syndrome | Lexicon Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX1033 | “An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects” NCT01411800 ↗ |
| Route | Oral | “Two 250 mg capsules will be administered for 500 mg dose” NCT01411800 ↗ |